

wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

  R^3 = R^4 = OMe or R^3 and R^4 form together -OCH_2O-,

- n is 0 to 8,

- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

  Z = O, S, or NH, and

  R^8 = 

  or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

  R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30}

alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, amino-(C_1-C_{30})-alkyl, or



where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl or C_2-C_{30} alkynyl, or C_1-C_{30} trihalogenoalkyl, and m is 0 to 4,

each of these groups including or not heteroatom(s),

or salt or tautomeric form thereof.

21. (Amended) A method of treating leukemia comprising administering to a human patient in need of such treatment using a subcutaneous mode of administration a harringtonine having the formula



wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

  R^3 = R^4 = OMe or R^3 and R^4 form together -OCH_2O-,

- n is 0 to 8,

- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

  Z = O, S, or NH, and

C2 cont



or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30} alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, amino-(C_1-C_{30})-alkyl, or



where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl or C_2-C_{30} alkynyl, or C_1-C_{30} trihalogenoalkyl, and m is 0 to 4,

each of these groups optionally including heteroatom(s),

or salt or tautomeric form thereof,

wherein said harringtonine is in a formulation in which

(i) the pH of the formulation is between 5.5 and 8.5,

(ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and

(iii) the level of chromatographic purity of harringtonine is higher than 99.7%.

---

28. (Amended) A method of treating leukemia comprising administering to a human patient in need of such treatment using a subcutaneous mode of administration a harringtonine salt or tautomeric form thereof, wherein the harringtonine has the formula



wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

  R^3 = R^4 = OMe or R^3 and R^4 form together -OCH_2O-,

- n is 0 to 8,

- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

  Z = O, S, or NH, and

R^8 = 

C3 cont

or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} clcloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30} alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, or amino-(C_1-C_{30})-alkyl, or



where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl or C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, m is 0 to 4,

each of these groups optionally including heteroatom(s),

wherein said harringtonine is in a formulation in which

(i) the pH of the formulation is between 5.5 and 8.5,

(ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and

(iii) the level of chromatographic purity of harringtonine is higher than 99.7%.